Should You Buy IBM (IBM) Stock Despite Quantum Breakthrough and 21% YTD Decline?

Key Highlights

• IBM achieved a significant quantum computing breakthrough by successfully connecting and cooling two cryogenic modules below 15 millikelvin, advancing its 2029 Quantum Starling timeline.
• The company introduced a groundbreaking dual-architecture mainframe chip at Hot Chips, utilizing 2nm technology capable of executing both IBM and Arm operating systems.
• IBM shares ended trading at $235.68 on Aug. 21, reflecting a 21% decline year-to-date and sitting 30% beneath the 52-week peak of $332.46.
• Second-quarter 2026 revenue increased a modest 1% to $17.2 billion, as IBM Z mainframe sales collapsed 42%, prompting management to reduce full-year revenue projections.
• Wall Street maintains a consensus “Moderate Buy” stance on IBM with an average target price of $251.87, suggesting potential upside of 8.4%.

Shares of IBM are currently priced at $235.68, registering a year-to-date decline exceeding 21%, despite the technology giant unveiling consecutive technical achievements that have captured industry attention.

International Business Machines Corporation, IBM

IBM revealed on Aug. 19 that it had successfully integrated and cooled two modular cryogenic systems into a unified ultra-cold environment, achieving temperatures beneath 15 millikelvin. This architecture is engineered to ultimately interconnect hundreds of quantum processors, addressing a fundamental engineering obstacle in quantum computing scalability.

This achievement directly supports IBM’s roadmap for the Quantum Starling system, scheduled for deployment in 2029. The company has pledged over $10 billion across the next five years to push quantum computing forward through research initiatives, manufacturing capabilities, and strategic acquisitions.

However, Wall Street’s response was notably subdued. IBM shares gained merely 1.9% when the announcement was made, only to retreat approximately 1.5% in the subsequent trading session. Market participants are evidently demanding more substantial catalysts beyond developmental milestones.

Revolutionary Dual-Architecture Processor Unveiled for Arm Ecosystem

IBM followed up on Aug. 24 with another major announcement at the Hot Chips conference: a dual-architecture mainframe processor engineered to simultaneously execute both IBM and Arm operating systems.

Manufactured using cutting-edge 2 nanometer technology, the processor features 11 high-performance cores operating above 5.7 GHz. It incorporates AI inference acceleration capabilities, an integrated data processing unit, and sophisticated encryption features. Each core can natively process both Arm and IBM Z instruction sets concurrently.

This processor emerged from IBM’s partnership with Arm, initially unveiled in April 2026. According to IBM, this strategic direction provides entry to a developer ecosystem encompassing over 22 million professionals globally.

Second Quarter Performance Weighs on Financial Outlook

These technological announcements unfold against a challenging financial landscape. IBM’s second-quarter 2026 results, disclosed on July 22, revealed revenue growth of only 1% year-over-year, reaching $17.2 billion. Net income decreased 1% to $2.2 billion. Non-GAAP EPS registered at $2.93, representing a 5% increase.

IBM Z mainframe revenue emerged as the primary weakness, plummeting 42% during the quarter as enterprise customers redirected capital toward AI infrastructure investments. Software revenue provided a positive counterbalance, advancing 5% to $7.8 billion. Consulting revenue remained stagnant at $5.3 billion.

IBM also revised its full-year guidance downward. Leadership now anticipates constant-currency revenue growth between 4% and 5%, retreating from the previous forecast exceeding 5%.

The stock touched a 52-week floor of $199.19 on July 23, immediately following the earnings release. Since that bottom, shares have rebounded approximately 12.4%.

Analysts currently value IBM at 19.13 times forward earnings, representing a discount relative to industry peers. The consensus recommendation stands at “Moderate Buy,” with an average target price of $251.87. CITIC Securities maintains a “Buy” rating with a $297 price objective. Susquehanna holds a “Neutral” stance with a $225 target.

Among 24 analysts tracking IBM, 11 assign “Strong Buy” ratings, 10 recommend “Hold,” and one rates it “Strong Sell.”